MaRS Excellence in Clinical Innovation and Technology Evaluation program

MaRS is a member of

MaRS
Ontario Network of Entrepreneurs
The challenge with the status quo

PRE-MARKET

Device Development

Device Manufacturing and Testing

Device Licensing

POST-MARKET

Pre-clinical

Clinical

Government Licensing

Adoption/listing
Developing Talent
Growing Ventures
Opening Markets
Our Future Matters
February 2015

MaRS EXCITE Concept

U

Pre-Market

Post-Market

Systematic review

Cost Effectiveness

Efficacy

Safety

Value (CE)

Affordability

Ethical & societal

Post-market conditions

Effectiveness

Systematic review

Cost Effectiveness (CE)

Efficacy

Safety

Value (CE)

Affordability

Ethical & societal

Post-market conditions

Cost Effectiveness

Systematic review

Regulation

Reimbursement

Unconditional No

Diffusion

Obsolescence

Time
EXCITE Overview

*Excellence in Clinical Innovation and Technical Evaluation*

**Pre-Market Partnership** formed February 2012 between government, OHTAC, the health system, regulators, academia, clinicians and industry in selection by the health system and protocol design by all

**Studies funded** by industry

Streamlines path to adoption of disruptive technologies through a **single harmonized process** that meets regulatory and reimbursement requirements

Process includes **evaluation, systematic review, economic analysis and “conditions of adoption” analysis**

**Housed at MaRS**, a neutral innovation space (MaRS) which provides flow-through of funds, **secretariat**, coordinating and quality support

**Executed by 4 academic Methodology Centres** working with 24 Research Hospitals
The EXCITE Collaboration Model

Management Board

MaRS EXCITE Secretariat

Scientific Collaborative

OHTAC (Reimbursement)

Safety Advisory Committee

Health Canada (Regulatory)

Methodology Centres

- Excellence in complex clinical trial design and execution in collaboration with 24 Research Hospitals
- Contracted in by EXCITE
- Design study with industry;
- Execute and publish the study
Examples of Projects in the Program

• Since February 2012, 42 companies applied

• Technologies selected:
  o 9 currently active (1 multinational, 2 US SMEs)
  o 5 under review through new applications

• Publicly discloseable projects are:
  o ApneaDx – Home sleep apnea test
  o Medtronic – Renal denervation for hypertension (discontinued)
  o Rna Diagnostics – Rna disruption for early prediction of CR to chemo in breast cancer
  o MyndTec – Electrical stimulation for voluntary upper limb movements in stroke
Looking ahead: Ontario Health Innovation Council (OHIC) report

Amongst its recommendations; four-year $20 million Health Technology Innovation Evaluation Fund to support pre-market evaluations and early adoption of home–grown innovative health technologies.

The fund will be managed by the Office of the Chief Innovation Strategist and will collaborate with Innovation Brokers like EXCITE that will be a single point of access to health system decision makers, test sites, and funding for development and commercialization of innovative health technologies.

To read the full report visit www.ohic.ca
Emerging EXCITE International Model

International Board

International Scientific Collaborative

EXCITE International Secretariat

Canada  USA  U.K.  N.Z.  Europe  Asia Pacific

Advice
OHTAC/ MaRS EXCITE Health Canada  Under Discussion

Evaluation
5 Ontario MCs
24 Research Hospitals

Our Future Matters
Our Future Matters

February 2015

Zayna Khayat
Director
zkhayat@marsdd.com

Lily Lo
Associate
llo@marsdd.com

Les Levin
Chief Scientific Officer
llevin@marsdd.com

Zayna Khayat
Director
zkhayat@marsdd.com

Adel Aziziyeh
Project Manager
aaziziyeh@marsdd.com

Lily Lo
Associate
llo@marsdd.com

MaRS is a member of

MaRS

Ontario Network of Entrepreneurs

For more information visit www.excite.marsdd.com
Twitter: #MaRSEXCITE

Or contact us at: